Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Monte Rosa TherapeuticsGLUE -1.13%32 EV-to-EBITDA is -9.27 as of Jul. 25, 2026. GuruFocus rates GLUE with a GF Score™ of 32/100. The stock has 5 warning signs investors should review. Among 402 Biotechnology companies, Monte Rosa Therapeutics ranks worse than 248755.97% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Monte Rosa Therapeutics's enterprise value is $1,297.29 Mil.
Monte Rosa Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-139.94 Mil. Therefore, Monte Rosa Therapeutics's EV-to-EBITDA for today is -9.27.
The historical rank and industry rank for Monte Rosa Therapeutics's EV-to-EBITDA or its related term are showing as below:
GLUE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -37.93 Med: -1.63 Max: 64.34
Current: -9.27
During the past 7 years, the highest EV-to-EBITDA of Monte Rosa Therapeutics was 64.34. The lowest was -37.93. And the median was -1.63.
GLUE's EV-to-EBITDA is ranked worse than 100% of 402
companies
in the Biotechnology industry
Industry Median: 12.2
vs GLUE: -9.27
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Monte Rosa Therapeutics (NAS:GLUE) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Monte Rosa Therapeutics's PE Ratio (TTM) for today is calculated as:
Monte Rosa Therapeutics's share price for today is $22.78.
Monte Rosa Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.634.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Monte Rosa Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monte Rosa Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Monte Rosa Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Monte Rosa Therapeutics's EV-to-EBITDA falls into.
Monte Rosa Therapeutics's current Enterprise Value is $1,297.29 Mil.
Monte Rosa Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-139.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monte Rosa Therapeutics (GLUE) has a EV-to-EBITDA of -9.27 as of Jul. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Monte Rosa Therapeutics. According to the industry distribution chart, Monte Rosa Therapeutics ranks #999999 out of 402 companies in the Biotechnology industry.
Is Monte Rosa Therapeutics' EV-to-EBITDA too high?
Monte Rosa Therapeutics' current EV-to-EBITDA is -9.27. Based on the distribution chart, Monte Rosa Therapeutics ranks #999999 out of 402 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Monte Rosa Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Monte Rosa Therapeutics' EV-to-EBITDA compare to SNDX and IOVA?
According to the Biotechnology industry distribution chart, Monte Rosa Therapeutics ranks #999999 out of 402 companies for EV-to-EBITDA. This places Monte Rosa Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 12.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.20, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Monte Rosa Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 12.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monte Rosa Therapeutics's current EV-to-EBITDA is -9.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monte Rosa Therapeutics stock overvalued right now?
Monte Rosa Therapeutics (GLUE) has a current EV-to-EBITDA of -9.27. The current EV-to-EBITDA is -9.27. Monte Rosa Therapeutics' overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Monte Rosa Therapeutics (GLUE), the current EV-to-EBITDA is -9.27 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
32GF Score
Get the complete analysis for GLUE
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLUE has been successfully added to your 
